Translation of Pluripotent Stem Cell Therapies for Blood Diseases (R01)

The summary for the Translation of Pluripotent Stem Cell Therapies for Blood Diseases (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Translation of Pluripotent Stem Cell Therapies for Blood Diseases (R01): This FOA issued by the National Heart, Lung, and Blood Institute, National Institutes of Health, encourages Research Project Grant (R01) applications from institutions and organizations that propose collaborative, multidisciplinary, multi-Project Director/Principal Investigator research for the development of new technologies needed to utilize stem cells in future cell therapies to treat sickle cell disease and other blood disorders. This initiative focuses on two key areas that are impediments to further progress: (1) development of techniques to efficiently generate hematopoietic cells by either differentiation of human pluripotent stem cells (PSC) or by cellular reprogramming to yield sufficient numbers of GMP quality cells for clinical evaluation; and (2) development of protocols that enable the efficient engraftment of hematopoietic cells derived from pluripotent stem cells or derived by cellular reprogramming. Each multidisciplinary application will designate two or more Project Directors/Principal Investigators. This program will be implemented in collaboration with the ongoing NHLBI Progenitor Cell Biology Consortium (http://www.progenitorcells.org/) and will add separate additional research projects. Extensive collaboration is expected between the existing Consortium Hubs, and the new group(s) are also expected to collaborate extensively with the Consortium Hubs.

Federal Grant Title:	Translation of Pluripotent Stem Cell Therapies for Blood Diseases (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PA-11-186
Type of Funding:	Grant
CFDA Numbers:	93.839
CFDA Descriptions:	Blood Diseases and Resources Research
Current Application Deadline:	Jan 07, 2014
Original Application Deadline:	Oct 05, 2013
Posted Date:	Mar 28, 2011
Creation Date:	Jun 10, 2011
Archive Date:	Feb 07, 2014
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign (non-U.S.) components of U.S. Organizations are not allowed.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immu...; • New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional); • Limited Competition: Sickle Pan-African Research Consortium Clinical Coordinating Center (...; • Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional); • Limited Competition: Sickle Africa Data Coordinating Center (U24 Clinical Trial Optional); • Improved Therapy for Hemophilia and Hereditary Bleeding Disorders; • Clinical Hematology Research Career Development Program (K12); • Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow F...
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...